CD4 and coronary artery disorder: A therapeutic vaccine capable of mounting efficient CD4+ and CD8+ T responses recognizing HBV and/or HDV antigens could be a promising approach for CHD therapy, if clearance of infected cells can be elicited in the suboptimal immunological background described above.